GO:0015218 pyrimidine nucleotide transmembrane transporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015218 describes a molecular function: the transfer of a pyrimidine nucleotide, a pyrimidine nucleoside esterified with orthophosphate, across a membrane.
• Pyrimidine nucleotide transmembrane transporter activity is distinct from nucleoside transport, which moves nucleosides rather than nucleotides.
• Equilibrative nucleoside transporters of the SLC29 family are the best-characterized proteins that handle pyrimidine nucleosides and related compounds, and they provide a mechanistic template for understanding nucleotide transport.
• Purinergic signaling and P2Z/P2X7 receptor activation can gate large membrane pores that permit nucleotide flux, linking this transport function to inflammation and epithelial ion transport.
• Energy-coupling factor transporters illustrate how ATP hydrolysis can drive substrate translocation across membranes, a paradigm relevant to pyrimidine nucleotide transport.
• Dysregulated nucleotide transport contributes to cystic fibrosis airway pathology and is a target for pharmacotherapeutic correction of ion transport defects.
Description
Pyrimidine nucleotide transmembrane transporter activity (GO:0015218) is a molecular function that enables the movement of pyrimidine nucleotides, such as CTP, UTP, and their deoxy derivatives, from one side of a biological membrane to the other. Pyrimidine nucleotides are essential for nucleic acid synthesis, energy metabolism, and signaling, so their compartmentalization must be tightly controlled. This GO term captures the transporter activity itself, not the downstream metabolic or signaling consequences, making it a precise annotation for functional genomics and drug-target studies.
pyrimidine nucleotide transmembrane transporter activity At A Glance
| GO ID | GO:0015218 |
|---|---|
| GO term | pyrimidine nucleotide transmembrane transporter activity |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Transfer of a pyrimidine nucleotide from one side of a membrane to the other |
| Substrate class | Pyrimidine nucleoside esterified with orthophosphate |
| Related transport families | SLC29 equilibrative nucleoside transporters; energy-coupling factor transporters |
| Disease relevance | Cystic fibrosis airway ion transport, purinergic inflammation, cancer metabolism |
What Is GO:0015218?
In plain terms, GO:0015218 describes the job of a membrane protein that carries a pyrimidine nucleotide across a lipid bilayer. The substrate is any compound consisting of a pyrimidine nucleoside esterified with orthophosphate, which distinguishes it from transporters of free nucleosides or nucleobases. The function is defined by the direction and membrane context of the transfer, and it is annotated as a molecular_function in the Gene Ontology.
Why Is pyrimidine nucleotide transmembrane transporter activity Important in Cell Biology?
Pyrimidine nucleotide transmembrane transporter activity matters because it controls the availability of nucleotide substrates for DNA and RNA synthesis, for glycosylation reactions, and for extracellular signaling. Defects in nucleotide transport can alter epithelial ion transport in cystic fibrosis and other airway diseases, and purinergic receptor activation can open nucleotide-permeable pores that amplify inflammation. Understanding this activity therefore connects basic membrane biology to clinically relevant processes in respiratory disease, cancer, and immune signaling.
• Controls intracellular pools of pyrimidine nucleotides needed for nucleic acid synthesis.
• Distinguishes nucleotide transport from nucleoside transport, which is mediated by different substrate specificities.
• Links to purinergic signaling through P2Z/P2X7 receptor pores that allow nucleotide flux.
• Contributes to epithelial ion transport regulation relevant to cystic fibrosis.
• Provides a target for pharmacotherapeutic correction of airway ion transport defects.
• Is relevant to energy-coupling factor transporter mechanisms that use ATP to drive substrate movement.
• Supports mucociliary transport function and airway histopathology in CF models.
• Offers a functional annotation for CRISPR screens and transporter gene characterization.
What Happens During pyrimidine nucleotide transmembrane transporter activity?
Substrate recognition at the membrane
In simple terms: The transporter first recognizes and binds a pyrimidine nucleotide at the membrane surface.
Transport begins when a membrane protein binds a pyrimidine nucleotide, a pyrimidine nucleoside esterified with orthophosphate, from the aqueous phase on one side of the membrane. Substrate specificity depends on the transporter family; equilibrative nucleoside transporters of the SLC29 family are known to handle nucleosides and related compounds, and their binding pockets discriminate among substrates.
Conformational change and translocation
In simple terms: The protein changes shape to move the nucleotide through the membrane.
After binding, the transporter undergoes conformational changes that expose the substrate to the opposite side of the membrane. Energy-coupling factor transporters provide a structural paradigm for how ATP binding and hydrolysis can drive such conformational cycles and substrate translocation.
Release and reset
In simple terms: The nucleotide is released on the other side, and the transporter resets for another round.
The pyrimidine nucleotide is released into the recipient compartment, and the transporter returns to its initial state to complete the transport cycle. This cycle can be coupled to cellular energy status, as seen in energy-coupling factor transporters that use ATP hydrolysis to power transport.
Integration with purinergic and ion transport
In simple terms: Nucleotide transport is often coordinated with signaling and ion movement across the same membrane.
P2Z/P2X7 purinoceptors can form large pores that permit nucleotide flux, linking pyrimidine nucleotide transport to purinergic signaling and inflammation. In epithelial tissues, purinergic stimulation and CFTR modulate epithelial Na+ channels, showing that nucleotide availability and ion transport are functionally coupled.
Key Genes Involved in GO:0015218 pyrimidine nucleotide transmembrane transporter activity
The following genes and protein families are experimentally linked to pyrimidine nucleotide transport, nucleoside transport, or the broader membrane transport machinery that informs GO:0015218.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC29A1 | Equilibrative nucleoside transporter 1; transports nucleosides and related compounds | Model for substrate recognition and inhibitor studies |
| SLC29A2 | Equilibrative nucleoside transporter 2; nucleoside transport | Comparative substrate specificity studies |
| SLC29A3 | Equilibrative nucleoside transporter 3; nucleoside transport | Tissue-specific transport function |
| SLC29A4 | Equilibrative nucleoside transporter 4; nucleoside and nucleobase transport | Broad substrate profiling |
| P2RX7 | P2X7 purinoceptor; forms large pores permeable to nucleotides | Purinergic signaling and inflammation |
| CFTR | Chloride channel that regulates epithelial ion transport | Cystic fibrosis airway ion transport |
| SCNN1A | Epithelial sodium channel subunit | CFTR and purinergic regulation of Na+ transport |
| SCNN1B | Epithelial sodium channel subunit | Airway ion transport studies |
| SCNN1G | Epithelial sodium channel subunit | Epithelial Na+ channel function |
| ECF transporter subunits | Energy-coupling factor transporter components | Structural basis of ATP-driven transport |
| SLC29 family members | Nucleoside and nucleobase transporter proteins | Family-wide functional annotation |
| P2Z receptor | Pore-forming purinergic receptor | Nucleotide flux and inflammation |
| Mucociliary transport genes | Airway clearance machinery | CF rat airway histopathology |
| CFTR modulators targets | Pharmacotherapeutic targets for ion transport | Drug development for CF |
| Purinergic signaling genes | Extracellular nucleotide signaling | Inflammation and epithelial function |
| Nucleoside transporter variants | Polymorphic transport proteins | Pharmacogenomics and substrate specificity |
| Energy-coupling factor genes | ATP-dependent transport systems | Mechanistic transport studies |
How Is pyrimidine nucleotide transmembrane transporter activity Regulated?
Pyrimidine nucleotide transmembrane transporter activity is regulated at multiple levels. Substrate availability and membrane potential influence transport rates, and purinergic receptor activation can open nucleotide-permeable pores that bypass classical transporters. In epithelial tissues, CFTR and purinergic stimulation coordinately regulate epithelial Na+ channels, indicating that nucleotide transport is integrated with ion transport regulatory networks. Pharmacological agents that target ion transport defects can also modulate the broader transport environment in cystic fibrosis airways.
pyrimidine nucleotide transmembrane transporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CFTR | Cystic fibrosis airway ion transport | CF rat airway model |
| P2RX7 | Purinergic inflammation | Knockout mouse or cell line |
| SLC29A1 | Nucleoside analog drug response | Overexpression and knockout cell lines |
| SCNN1A/B/G | Epithelial Na+ channel regulation | Epithelial cell models |
| ECF transporter genes | ATP-driven transport mechanisms | Bacterial transporter reconstitution |
Cystic fibrosis and airway ion transport
Cystic fibrosis is characterized by defective ion transport in the airway epithelium, and pharmacotherapeutic strategies aim to correct these defects. Purinergic stimulation and CFTR regulate epithelial Na+ channels, linking nucleotide signaling to the ion transport abnormalities seen in CF. Red ginseng aqueous extract has been shown to improve mucociliary transport dysfunction and histopathology in CF rat airways, highlighting the therapeutic relevance of transport-modulating interventions.
Purinergic inflammation
P2Z purinoceptors can form large pores that permit nucleotide flux, contributing to inflammatory signaling. This connects pyrimidine nucleotide transport activity to immune cell activation and tissue inflammation, making it a potential target for anti-inflammatory strategies.
Cancer metabolism and nucleoside analogs
Equilibrative nucleoside transporters of the SLC29 family mediate the uptake of nucleoside analogs used in cancer therapy, and their substrate specificity determines drug efficacy. Understanding pyrimidine nucleotide transport mechanisms can inform the design of more effective nucleoside-based therapeutics.
From pyrimidine nucleotide transmembrane transporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate transporter alter pyrimidine nucleotide flux? | Knockout cell line |
| Does a point mutation change substrate specificity? | Point-mutation knock-in |
| Can a tagged transporter be tracked in live cells? | Tagged knock-in |
| Does overexpression increase nucleotide uptake? | Overexpression cell line |
| Which genes regulate transporter expression? | CRISPR library screening |
| What is the structural basis of transport? | Reconstituted proteoliposome assays |
How to Study the pyrimidine nucleotide transmembrane transporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled uptake assay | Transporter-mediated nucleotide influx | Substrate specificity studies |
| Fluorescent nucleotide uptake | Real-time transport activity | Live-cell imaging |
| Ussing chamber | Epithelial ion transport | CFTR and Na+ channel function |
| Cryo-EM | Transporter structure and conformational states | Mechanistic studies |
| CRISPR knockout screen | Genes required for transport | Functional genomics |
| Overexpression | Gain-of-function transport | Candidate gene validation |
| Patch clamp | Pore permeability and currents | Purinergic receptor studies |
Transport assays
Radiolabeled or fluorescent pyrimidine nucleotide uptake assays measure transporter activity directly in cell lines or reconstituted systems. These assays can distinguish nucleotide transport from nucleoside transport based on substrate specificity.
Electrophysiology and pore assays
Purinergic receptor pore formation can be studied using electrophysiology and dye uptake assays to assess nucleotide permeability. Epithelial ion transport can be measured using Ussing chamber systems to evaluate CFTR and Na+ channel function.
Structural biology
Cryo-EM and X-ray crystallography of energy-coupling factor transporters reveal how ATP binding and hydrolysis drive conformational changes during substrate translocation. These structures provide templates for modeling pyrimidine nucleotide transporters.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout screens can identify genes required for pyrimidine nucleotide transport and downstream metabolic pathways. Hits can be validated with targeted knockout and overexpression models.
How CRISPR Can Be Used to Study GO:0015218 pyrimidine nucleotide transmembrane transporter activity
Knockout
CRISPR knockout of candidate transporter genes can abolish pyrimidine nucleotide transport and reveal downstream metabolic consequences. Knockout models are essential for establishing causality between a gene and GO:0015218 activity.
Point Mutation
Point mutations introduced by CRISPR base editing or homology-directed repair can alter substrate binding residues and test their role in pyrimidine nucleotide recognition. Such models help map the structure-function relationship of the transporter.
Knock-in
Knock-in of epitope tags or fluorescent proteins allows visualization and purification of transporters for biochemical and imaging studies. Tagged knock-in models preserve endogenous regulation of the transporter.
Overexpression
CRISPR activation or cDNA overexpression can increase transporter levels to study gain-of-function effects on nucleotide flux and cellular metabolism. Overexpression models are useful for drug screening and substrate profiling.
How EDITGENE Supports pyrimidine nucleotide transmembrane transporter activity Research
Researchers studying pyrimidine nucleotide transmembrane transporter activity-related genes often need to determine whether a candidate gene is causally involved in transport, substrate specificity, or downstream disease phenotypes. EDITGENE provides CRISPR-based cell model services that enable precise genetic perturbations for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for pyrimidine nucleotide transmembrane transporter activity research.
Frequently Asked Questions About pyrimidine nucleotide transmembrane transporter activity
What is pyrimidine nucleotide transmembrane transporter activity?
It is a molecular function (GO:0015218) that enables the transfer of a pyrimidine nucleotide from one side of a membrane to the other.
What genes are involved in pyrimidine nucleotide transmembrane transporter activity?
Genes in the SLC29 family, such as SLC29A1 and SLC29A2, are involved in nucleoside and related transport, and P2RX7 contributes to nucleotide-permeable pores.
How is pyrimidine nucleotide transport different from nucleoside transport?
Pyrimidine nucleotide transport moves nucleotides, which are nucleosides esterified with phosphate, whereas nucleoside transport moves nucleosides without phosphate.
What diseases are linked to pyrimidine nucleotide transport?
Cystic fibrosis airway ion transport defects and purinergic inflammation are linked to nucleotide transport and signaling.
What methods study pyrimidine nucleotide transmembrane transporter activity?
Radiolabeled uptake assays, fluorescent nucleotide imaging, Ussing chamber electrophysiology, and cryo-EM are commonly used.
Can CRISPR be used to study pyrimidine nucleotide transporters?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can test the function of candidate transporter genes.
What is the role of CFTR in nucleotide transport?
CFTR regulates epithelial ion transport and is functionally coupled to purinergic signaling and Na+ channel activity.
How do purinergic receptors relate to nucleotide transport?
P2Z/P2X7 purinoceptors can form large pores that permit nucleotide flux, linking transport to inflammation.
What is an energy-coupling factor transporter?
It is a bacterial transporter that uses ATP hydrolysis to drive substrate translocation across membranes.
Why is pyrimidine nucleotide transport important for cancer therapy?
SLC29 transporters mediate the uptake of nucleoside analogs used in cancer treatment, affecting drug efficacy.
Conclusion
Pyrimidine nucleotide transmembrane transporter activity (GO:0015218) is a precisely defined molecular function that governs the movement of pyrimidine nucleotides across membranes. Its study connects membrane transport biology to purinergic signaling, epithelial ion transport, and nucleoside-based therapeutics. CRISPR-based models and functional assays provide powerful tools to dissect the genes and mechanisms underlying this activity.
References
- 1. Hickman SE et al.. 1996. P2Z purinoceptors.. Ciba Found Symp 198:71-83; discussion 83-90 PMID: 8879819
- 2. Baldwin SA et al.. 2004. The equilibrative nucleoside transporter family, SLC29.. Pflugers Arch 447(5):735-43 PMID: 12838422
- 3. Young JD et al.. 2008. Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins.. Xenobiotica 38(7-8):995-1021 PMID: 18668437
- 4. Clunes MT et al.. 2008. Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis.. Curr Opin Pharmacol 8(3):292-9 PMID: 18468487
- 5. Cho DY et al.. 2023. Red ginseng aqueous extract improves mucociliary transport dysfunction and histopathology in CF rat airways.. J Cyst Fibros 22(6):1113-1119 PMID: 37704464
- 6. Kunzelmann K et al.. 2001. Mechanisms of the inhibition of epithelial Na(+) channels by CFTR and purinergic stimulation.. Kidney Int 60(2):455-61 PMID: 11473626
- 7. Wang T et al.. 2013. Structure of a bacterial energy-coupling factor transporter.. Nature 497(7448):272-6 PMID: 23584587
- 8. Donaldson SH et al.. 2013. New pulmonary therapies directed at targets other than CFTR.. Cold Spring Harb Perspect Med 3(6) PMID: 23732851
